What is HC Wainwright’s Estimate for RARE FY2025 Earnings?

Ultragenyx Pharmaceutical Inc. (NASDAQ:RARE) – Research analysts at HC Wainwright reduced their FY2025 earnings per share estimates for Ultragenyx Pharmaceutical in a report released on Monday, January 5th. HC Wainwright analyst R. Selvaraju now anticipates that the biopharmaceutical company will earn ($5.26) per share for the year, down from their previous forecast of ($4.85). HC Wainwright has a “Buy” rating and a $60.00 price objective on the stock. The consensus estimate for Ultragenyx Pharmaceutical’s current full-year earnings is ($5.18) per share. HC Wainwright also issued estimates for Ultragenyx Pharmaceutical’s Q4 2025 earnings at ($0.71) EPS, Q1 2026 earnings at ($1.63) EPS, Q2 2026 earnings at ($1.40) EPS, Q3 2026 earnings at ($1.30) EPS, Q4 2026 earnings at ($1.00) EPS and FY2026 earnings at ($5.32) EPS.

Ultragenyx Pharmaceutical (NASDAQ:RARE) last released its quarterly earnings results on Tuesday, November 4th. The biopharmaceutical company reported ($1.81) earnings per share (EPS) for the quarter, missing the consensus estimate of ($1.23) by ($0.58). Ultragenyx Pharmaceutical had a negative return on equity of 414.17% and a negative net margin of 91.95%.The business had revenue of $159.93 million during the quarter, compared to the consensus estimate of $167.42 million. During the same period in the previous year, the company posted ($1.40) EPS. The company’s revenue for the quarter was up 14.6% compared to the same quarter last year.

A number of other research firms also recently commented on RARE. Robert W. Baird dropped their price target on shares of Ultragenyx Pharmaceutical from $72.00 to $47.00 and set an “outperform” rating on the stock in a research report on Tuesday, December 30th. TD Cowen lowered their price objective on shares of Ultragenyx Pharmaceutical from $86.00 to $75.00 and set a “buy” rating on the stock in a research note on Wednesday, November 5th. Jefferies Financial Group cut their target price on Ultragenyx Pharmaceutical from $114.00 to $63.00 and set a “buy” rating for the company in a research report on Tuesday, December 30th. Leerink Partners decreased their price target on Ultragenyx Pharmaceutical from $80.00 to $70.00 and set an “outperform” rating for the company in a research note on Tuesday, December 30th. Finally, Guggenheim dropped their price objective on Ultragenyx Pharmaceutical from $64.00 to $52.00 and set a “buy” rating on the stock in a research note on Monday. Sixteen investment analysts have rated the stock with a Buy rating, one has assigned a Hold rating and one has given a Sell rating to the company’s stock. Based on data from MarketBeat.com, the company presently has a consensus rating of “Moderate Buy” and an average price target of $72.29.

Ultragenyx Pharmaceutical Stock Up 7.4%

RARE stock opened at $24.20 on Wednesday. The company has a 50-day simple moving average of $32.12 and a 200 day simple moving average of $31.46. The company has a market capitalization of $2.33 billion, a P/E ratio of -4.07 and a beta of 0.15. Ultragenyx Pharmaceutical has a fifty-two week low of $18.41 and a fifty-two week high of $46.50.

Insider Activity

In other news, CFO Howard Horn sold 7,942 shares of the stock in a transaction on Monday, October 13th. The stock was sold at an average price of $31.51, for a total transaction of $250,252.42. Following the completion of the sale, the chief financial officer owned 98,227 shares in the company, valued at approximately $3,095,132.77. This represents a 7.48% decrease in their position. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through this hyperlink. Insiders sold a total of 11,108 shares of company stock valued at $365,262 over the last quarter. 5.50% of the stock is currently owned by corporate insiders.

Institutional Investors Weigh In On Ultragenyx Pharmaceutical

Institutional investors and hedge funds have recently modified their holdings of the stock. Covestor Ltd boosted its position in shares of Ultragenyx Pharmaceutical by 26.0% in the 3rd quarter. Covestor Ltd now owns 1,787 shares of the biopharmaceutical company’s stock valued at $54,000 after purchasing an additional 369 shares during the period. Huntington National Bank lifted its stake in Ultragenyx Pharmaceutical by 56.2% during the third quarter. Huntington National Bank now owns 1,092 shares of the biopharmaceutical company’s stock valued at $33,000 after buying an additional 393 shares in the last quarter. Teacher Retirement System of Texas boosted its holdings in shares of Ultragenyx Pharmaceutical by 1.8% in the second quarter. Teacher Retirement System of Texas now owns 22,773 shares of the biopharmaceutical company’s stock worth $828,000 after buying an additional 404 shares during the period. Xponance Inc. boosted its holdings in shares of Ultragenyx Pharmaceutical by 3.1% in the third quarter. Xponance Inc. now owns 13,494 shares of the biopharmaceutical company’s stock worth $406,000 after buying an additional 406 shares during the period. Finally, China Universal Asset Management Co. Ltd. increased its position in shares of Ultragenyx Pharmaceutical by 2.3% in the second quarter. China Universal Asset Management Co. Ltd. now owns 18,988 shares of the biopharmaceutical company’s stock worth $690,000 after acquiring an additional 434 shares in the last quarter. 97.67% of the stock is owned by institutional investors and hedge funds.

Ultragenyx Pharmaceutical News Summary

Here are the key news stories impacting Ultragenyx Pharmaceutical this week:

• Positive Sentiment: CEO Emil D. Kakkis will present at the 44th Annual J.P. Morgan Healthcare Conference on Jan. 12, increasing senior-management visibility and providing a live/replay channel for investors to hear program updates and commercialization progress. Ultragenyx CEO to Present at J.P. Morgan Healthcare Conference
• Positive Sentiment: HC Wainwright revised several near-term EPS estimates upward and raised its FY2026 outlook (and maintains a “Buy” rating with a $60 price target), signaling analyst confidence in Ultragenyx’s longer-term revenue profile and helping sentiment. HC Wainwright analyst note (MarketBeat summary)
• Neutral Sentiment: Institutional activity is mixed but notable: large additions from some funds (e.g., FMR materially increased exposure) while others trimmed positions, which can amplify intraday moves but doesn’t single-handedly direct the trend. Quiver / institutional holdings summary
• Negative Sentiment: Guggenheim cut its price target to $52, which can weigh on upside expectations and headline-driven sentiment even if other analysts remain more bullish. Guggenheim Lowers Ultragenyx Price Target to $52
• Negative Sentiment: Reports pointing to a clinical setback have surfaced, raising execution and development risk for pipeline programs; such headlines typically pressure biotech names until details or remediation plans are clear. Ultragenyx Faces Mounting Challenges After Clinical Setback
• Negative Sentiment: An investor alert from Pomerantz LLP signals an active investigation into potential claims by Ultragenyx investors, adding legal/settlement risk and potential headline volatility. Pomerantz Investigates Claims on Behalf of Ultragenyx Investors

About Ultragenyx Pharmaceutical

Ultragenyx Pharmaceutical Inc is a biopharmaceutical company focused on developing and commercializing therapies for rare and ultra-rare genetic disorders. Since its founding in 2010 and headquarters in Novato, California, the company has built expertise in protein replacement therapies, small molecules and gene therapy approaches to address high-unmet medical needs. Ultragenyx applies a precision medicine model, leveraging both in-house research and strategic collaborations to advance its product pipeline from discovery through regulatory approval.

The company’s commercial portfolio includes Crysvita (burosumab-tmyl) for X-linked hypophosphatemia, Mepsevii (vestronidase alfa-vjbk) for mucopolysaccharidosis VII and Dojolvi (triheptanoin) for long-chain fatty acid oxidation disorders.